May 01, 2014 - 2:46 am
Thehas approved Cyramza (ramucirumab) 10mg/mL injection for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction ( ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
alexandra phan md says :"Ramucirumab is a fully humanized monoclonal antibody against the vascular endothelial growth factor receptor 2 (VEGFR2). This is a biological agent that has been tested in several cancers including stomach and lung cancers. On Monday, the FDA approved this agent for the treatment of patients with advanced gastric or gastro-esophageal junction (GEJ) cancers. ......"